Liraglutide

Saxenda

Active ingredient
liraglutide
Class
GLP-1 receptor agonist
Route
Once-daily subcutaneous injection
Maker
Novo Nordisk

Educational only. This is educational, not medical advice. Everyone's body responds differently. Talk to your clinician before starting, stopping, changing, or tapering any medication, and work with your physician and a registered dietitian to personalize your approach.

Overview

Saxenda is liraglutide, an earlier, shorter-acting GLP-1 receptor agonist approved for weight management. Unlike the once-weekly newer drugs, it is injected once daily.

It works through the same GLP-1 pathway but tends to produce smaller average weight loss than semaglutide or tirzepatide, and the daily dosing is less convenient.

Approval and use

Approved forChronic weight management in adults and adolescents
Weight useOn-label for weight management.

Typical titration (informational)

Saxenda escalates over about five weeks from 0.6 mg daily up to a 3 mg maintenance dose.

The prescriber individualizes the pace based on tolerance.

Background only.

Expected timeline

Average weight loss in trials was in the high single digits percent of body weight, less than the newer once-weekly agents.

Common side effects

  • Nausea (common early)
  • Diarrhea, constipation
  • Low blood sugar when combined with other diabetes medicines
  • Injection-site reactions
The off-ramp

What happens when you stop Saxenda

In the regain meta-analysis, liraglutide 3 mg showed the smallest rebound of the studied drugs (around 1.5 kg), partly because its on-treatment loss is smaller, so there is less to regain.

The maintenance principles are identical: the loss you keep depends on the habits you build, not on which molecule you used.

The maintenance plan for after Saxenda

Cost

Cash price has historically been somewhat lower than the newer agents but still substantial. Verify current pricing.

FAQ

Frequently asked questions

Why is Saxenda injected daily?

Liraglutide is shorter-acting than semaglutide or tirzepatide, so it requires daily dosing. The newer once-weekly drugs are more convenient and tend to produce more weight loss.

Sources & further reading

Every claim on this page is drawn from peer-reviewed research, clinical trials, or recognized health authorities. Read the source before making any decision about your health.

  1. [1]Rebound or Retention: A Meta-Analysis of Weight Regain After Discontinuation of GLP-1 Receptor AgonistsNIH/PMC
  2. [2]Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regressionNIH/PMC

Compare

Key terms

Related guides